Jenthera Therapeutics
Jenthera Therapeutics is a seed stage therapeutics company introducing a novel protein-based gene editing platform delivering solutions to the major challenges currently facing CRISPR therapeutics: safety, precision corrections and targeted delivery. Our patented technology allows for the rapid development of high efficacy non-viral gene editing complexes achieving unprecedented levels of efficiency in cellular delivery, high frequencies of corrective precision repair and safety from off-target effects. We are looking to raise a 2M$ seed round to finance our EML4-ALK non-small cell lung cancer in vivo validation leading to a Series A in Q4-2021 that will fund IND enabling preclinical studies and PhaseI/II clinical trials.
Presenter: Philip Roche, CEO
Read More
JN Nova Pharma Inc.
JN Nova Pharma Inc’s lead therapeutic molecule, JN2019, is a potent corona viral neutralizing agent, acting via an enhanced ACE2 decoy, which inhibits viral entry and is immunologically conjugated to cause viral clearance. By simultaneously replacing the lost ACE2 function, it potentially will counteract the deleterious effects of acute respiratory disease syndrome (ARDS) and reduce pathogenic innate immune activation and inflammation caused by the virus.
Presenter: John Gillard, CEO
Read More
KA Imaging Inc
KA Imaging has created color x-ray (Reveal™)which allows for soft tissue and bone separation resulting in better patient outcomes. Reveal™, has received USA FDA 510(k) clearance and Health Canada approval and the company is focusing on commercialisation. KA is raising $25M USD for commercialization infrastructure (sales, service and applications), marketing the hardware-as-a-service revenue model and AI development.
Presenter: Amol Karnick, President & CEO
Read More
Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
MedBiome
MedBiome develops precision microbiome therapeutic and nutritional products to improve human health. MedBiome has a novel platform to screen compounds for their effects on living human microbiomes in 96 well plates. We use this technology for: 1) the development of precision microbiome nutritional and therapeutics products targeting specific microbiome metabolites with a focus on pediatric IBD and new programs in gut-brain axis, and Chronic Kidney Disease. 2) partnering with biotechnology and pharmaceutical companies seeking to screen their proprietary drugs, nutritional compounds, natural compounds, and other compounds against panels of human/animal microbiomes.
Presenter: Daniel Figeys, President
Read More
Mesentech
Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These chemical conjugates liberate the active pharmaceutical only in the targeted tissue thereby eliminating side effects caused by systemic exposure. Mesentech’s lead program is a bone-targeted anabolic that stimulates bone regeneration. It is indicated for severe pediatric osteoporosis caused by brittle bone disease, Duchenne muscular dystrophy and as a consequence of steroid treatment.
Presenter: Jonathan Polak, CEO
Read More
My Intelligent Machines
My Intelligent Machines (MIMs), based in Montreal, is a leader in artificial intelligence applied to life sciences. We provide Biopharma and Agtech companies with augmented intelligence systems enabling life scientists working in this space to model patients, cells, tissues or farm animals to develop more efficient and personalized treatments and agro-products. We are closing our Series A of 5M$ by Jan 2021. The proceeds will be used for the scaling phase, to consolidate our leadership in Canada, USA & Europe & team growth.
Presenter: Sarah Jenna, CEO
Read More
Mobio Interactive
Mobio Interactive is a revenue-generating digital therapeutics company that develops and commercializes clinically validated and objectively quantified software to prevent, measure and treat mental illness. Mobio’s recent progress includes completion of a clinical trial with cancer patients, demonstrating equivalent effect sizes on psychological wellbeing from the DTx Am Mindfulness as compared to group psychotherapy. Mobio is raising Series A capital to support clinical trials, IP protection, payor & partner negotiations, regulatory approval, and DTx sales.
Presenter: Bechara Saab, CEO
Read More
Morphocell Technologies
Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its allogeneic stem cell-derived engineered liver tissues (ELT). Its mission is to transform the treatment of liver disease by the means of cell therapy. With $2.1M in pre-seed funding, we significantly de-risked the technology, collected compelling efficacy/safety data and addressed key scalability hurdles in manufacturing. We are seeking $4.5M to confirm the efficacy and safety of the ELT in large animals. Achieving this key value inflection point would trigger a larger series A investment from already engaged parties, thus enabling pre-clinical development up to CTA/IND application.
Presenter: Massimiliano Paganelli, Co-founder and CEO
Read More
MY01
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes. We are commercial and saving limbs with our MY01 Continuous Intracompartment Pressure Monitor.
Presenter: Charles Allan, CEO
Read More
Nanovista Inc.
Nanovista is developing novel imaging agents for surgical oncology with the lead product, CF800, enabling cancer surgeons to visualize tumors in real time during surgery. Even the most skilled surgeons capture as little as 30-60% of the tumor margins in challenging disease areas. Nanovista's CF800 liposomal imaging agent accumulates specifically at tumor margins and is ideally suited to visualize all solid tumors. CF800 works with existing operating room near-infrared imaging equipment and illuminates tumors both at the surgery planning phase and inside the operating room, with the potential to significantly improve cancer surgery outcomes. The company is raising capital for Phase I development of CF800 in lung cancer and head and neck cancer.
Presenter: Anton Neschadim, Chief Executive
Read More
Neurovine
Neurovine is a Series A stage prescription digital health platform that uses AI and connected wearables to improve brain recovery after a concussion. The proceeds will allow Neurovine to complete the second clinical trial and the regulatory process and to launch the product with Canadian physiotherapists and sports medicine physicians who have established billing codes.
Hear more from this company during the Early Technology Showcase.
Presenter: Ashleigh Kennedy, Founder
Read More
Nightingale.ai
Nightingale.ai is in development of a computer vision-based mobile application for end-to-end automation of physiotherapy management of patients post total hip and knee replacement. This self-assessment and treatment planning tool enable remote personalized care in a cost-effective manner. The company is currently in pre-seed stage. The proceeds from seed financing will be used on creating the prototype of the first-of-its-kind computer vision-based functional tests and treatment planning, conducting pre-clinical trials, and covering essential developer compensation.
Hear more from this company during the Early Technology Showcase.
Presenter: Sameer Chunara, Co-founder and CEO
Read More
Notogen
Notogen is a preclinical-stage biotechnology company developing a novel regenerative biologic therapy for degenerative disc disease (i.e. chronic back and neck pain caused by degenerating spinal discs), a disease indication with no disease modifying treatments that is the largest unmet need in orthopedics and one of the largest unmet needs in healthcare. Notogen has had a successful pre-IND meeting with the FDA, has published impressive large animal in vivo data, has raised funding to complete its cGMP manufacturing and its IND-filing, and is now looking to raise a Series A round to finance its Phase I/IIa clinical trial and beyond.
Presenter: Gary Margolis, CEO
Read More
Nuro
NURO is an award-winning start-up from Waterloo, Ontario, which has developed NUOS, the Neural Operating System. With NUOS, incapacitated individuals in various states of Akinetic Mutism (due to Stroke, Trauma or Neurodegeneration) can now communicate and compute using brain signals. NUOS works instantly and without any surgery. NUOS is Health Canada cleared, US IRB cleared and US FDA cleared as the only non-invasive treatment of its kind. NUOS has been released in 3 editions after 6 years of R&D, 5 accelerators in Canada and Silicon Valley and over $1M of funding by SOSV / INDIE BIO, top medical doctors, The Ontario Centres of Excellence and other parties including Canada's FedDev, NRC-IRAP, MaRs, Mitacs, MIT, Google and more.
Presenter: Francois Gand, Founder and CEO
Read More
Oncoustics
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Oncoustics applies AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics is a clinical-stage company with partnerships with several ultrasound OEMs, and FDA pre-sub and trials this year. Oncoustics is raising Series A capital to bring the first product to market (FDA clearance), and continue growing the data library for new indications, as well as grow the team.
Presenter: Ahmed El Kaffas, Founder
Read More
Orion Biotechnology Canada
Orion Biotechnology is a clinical stage biotechnology company developing GPCR-targeted therapeutics for the treatment of cancer and other serious diseases. This novel scientific approach is enabled by Orion’s proprietary high-throughput drug discovery platform. Our disruptive analog-based technologies position OB to become a premier GPCR-focused company to deliver next generation therapeutics not only for Orion’s pipeline, but also in collaboration with other biopharmaceutical companies. We plan to advance our lead candidate into Phase 1b/2a trial in Oncology and complete lead optimization of 2 additional drug candidates.
Presenter: Antaole Klepatskyi, COO
Read More
Ovensa Inc.
Ovensa Inc. is a preclinical stage biotech company advancing its siRNA lead candidate silencing galectin-1 (Gal-1) overexpression in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors as a combination therapy in head & neck cancer. Ovensa currently works with pharmaceutical companies to formulate their drugs into nanoparticles using Ovensa's TRIOZAN™ drug delivery platform. Most of the collaborations are related to siRNA or mRNA therapeutics where Ovensa offers a non-lipidic approach for intranasal, IV or vaccines delivery.
Presenter: Stephane Gagne, President & CEO
Read More
PanTHERA CryoSolutions Inc
PanTHERA CryoSolutions Inc. (PanTHERA) is a Canadian Corporation that designs and manufacturers pre-formulated cryopreservation solutions for cells and tissues used in the clinical and research markets. The majority of cellular damage during cryopreservation occurs as a result of the uncontrolled growth of ice during storage at sub-zero temperatures followed by subsequent warming and thawing. The PanTHERA technology has the unique ability to control ice crystal size and growth throughout the cryopreservation process and thus maintain superior recoveries and cellular function after extended frozen storage.
Presenters: Robert Ben, Co-founder and CSO
Read More
Perceiv
Perceiv is an AI-based digital biomarkers company specializing in the field of precision medicine. We are dedicated to reducing risks for patients and making clinical trials more cost-effective through advanced machine learning algorithms. We have secured $360K (USD) in non-dilutive public funding and we are seeking $2M (USD) in dilutive investment. These proceeds would go into making key hires (scientists, developers, and business development staff), operationalizing and commercializing our Alzheimer’s solution (product launch), supporting partnerships for data access with pharmaceutical companies and hospitals, and further improving our platform to accelerate new product development, and support the development new products (cardiovascular diseases).
Presenter: Christian Dansereau, CEO
Read More
